Merck & Co (MRK)
$83.02 0.51 (0.62%)
18:30 EDT MRK Stock Quote Delayed 15 Minutes
Previous Close $83.02
Market Cap 223.35B
PE Ratio 143.14
Volume (Avg. Vol.) 6.66M
Day's Range 82.38 - 83.28
52-Week Range 66.10 - 87.35
Dividend & Yield 1.92 (2.31%)
MRK Stock Predictions, Articles, and Merck & Co News
- From InvestorPlace
- From the Web
A divided Federal Reserve is a new issue for investors to consider. Read more about what happened in the Dow Jones today.
The stock charts of MSFT, FB and MRK have earned a closer technical look as the new trading week kicks off.
Bristol-Myers Squibb stock touched a multi-year low last month. But the BMY stock price is cheap enough now to take on real risks.
Here we looked for five of the Street’s highest-rated Dow Jones stocks right now. As you will see all five of these stocks show a firm ‘Strong Buy’ Street consensus. That's based on all the ratings received by each stock over the last three months.
Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?
Options trading was buzzing in Bed Bath & Beyond, CVS, and Merck on Thursday. Here are the metrics that matter moving forward.
The stock charts of HollyFrontier, Activision Blizzard and Vertex Pharmaceuticals are poised to end the trading week in a pivotal situation.
Drug stocks are falling on fears of President Trump's next move on drug prices. Here's a look at the charts.
As has been noted in this space, market participants are pricing in the following Fed facts: no interest rate cut this month and no cuts totaling 50 basis points this year. Hope burns eternal for a rate reduction of 25 basis points, but Powell's two-day testimony and the June meeting minutes could indicate otherwise.
Despite all the fear around prescription drug prices, there are some excellent healthcare stocks to buy for interested investors.
Play a friendly and widening price spread in biotech stocks with a well-place purchase in Merck and an equally smart short in AbbVie.
Investors are punishing Bristol-Myers on the markets more than they should. BMY stock's acquisition of Celgene isn't the only reason.
Smaller-capitalization biotechs can be riskier investments, but EXEL stock has more than just promise off and on the price chart and is readying to be purchased.
Pfizer, Walgreens and Merck are just three of the Dow Jones stocks that have kept the index from doing as well as other market indices have this year.
These ten stocks aren't exactly household names, but they each deserve a spot in a list of small-cap stocks to buy now for traders that can deal with the risk for the potential of high reward.
From The Street
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!